Clinical Trial

A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.

Name: A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer. — clinical trial record (NCT07557004)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

Evaluate the efficacy and safety of the SH3765 tablet combined with fulvestrant in the treatment of patients with advanced HR-positive breast cancer

Trial Details

NCT Number	NCT07557004
Lead Sponsor	Nanjing Sanhome Pharmaceutical, Co., Ltd.
Conditions	HR+ / HER2- Advanced Breast Cancer
Enrollment	30 participants
Start Date	2025-09-30
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-29